Published 2018 | Version v1
Journal article

Production, quality control, biodistribution and imaging studies of 177Lu-PSMA-617 in breast adenocarcinoma model

  • 1. Nuclear Science and Technology Research Institute, Tehran (Iran, Islamic Republic of). Materials and Nuclear Fuel Research School
  • 2. International Atomic Energy Agency (IAEA), Vienna (Austria). Radioisotope Products and Radiation Technology Section
  • 3. Nuclear Science and Technology Research Institute, Tehran (Iran, Islamic Republic of). Radiation Application Research School

Description

177Lu-PSMA-617 therapeutic agent was prepared successfully under optimized condition of pH=4.5, molar ratio of metal to ligand 1:10, temperature of 95 C and 40 min reaction time. 177LuCl3 was obtained with specific activity of 70-80 GBq/mg by the thermal neutron irradiation (5 x 1013 n cm-2 s-1) of the enriched Lu2O3 (52% 176Lu) samples. The radionuclidic purity of 177LuCl3 (>99%) was checked by a HPGe detector. The radiochemical purities of 177LuCl3 solution and 177Lu-PSMA-617 compound (>98%) were checked by ITLC and HPLC techniques and stability studies were assayed in the presence of human serum. Biodistribution and imaging assessments in the breast adenocarcinoma-bearing mice showed a major accumulation of activity in the tumor and kidneys tissues, as the expression site of PSMA molecule and the main route of excretion, respectively.

Additional details

Publishing Information

Journal Title
Radiochimica Acta
Journal Volume
106
Journal Issue
6
Journal Page Range
p. 507-513
ISSN
0033-8230
CODEN
RAACAP